Literature DB >> 17032499

TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions.

Nuno Cerveira1, Franclim R Ribeiro, Ana Peixoto, Vera Costa, Rui Henrique, Carmen Jerónimo, Manuel R Teixeira.   

Abstract

TMPRSS2-ETS gene fusions have been found recurrently in prostate carcinomas, but not in the presumed precursor lesion, high-grade prostatic intraepithelial neoplasia (HGPIN). However, HGPIN lesions may share chromosomal changes with prostate cancer. To determine the relative order of genetic events in prostate carcinogenesis, we have analyzed 34 prostate carcinomas, 19 paired HGPIN lesions, 14 benign prostate hyperplasias, and 11 morphologically normal prostatic tissues for TMPRSS2-ERG and TMPRSS2-ETV1 rearrangements and genomic imbalances. TMPRSS2 exon 1 was fused in-frame with ERG exon 4 in 17 of 34 (50%) prostate carcinomas and in 4 of 19 (21%) HGPIN lesions, but in none of controls. The findings were further validated by sequencing analysis and by the real-time polymerase chain reaction quantification of TMPRSS2-ERG fusion transcript and the ERG exons 5/6:exons 1/2 expression ratio. Chromosome copy number changes were detected by comparative genomic hybridization in 42% of clinically confined carcinomas and in none of the 16 HGPIN lesions analyzed. We demonstrate for the first time that the TMPRSS2-ERG fusion gene can be detected in a proportion of HGPIN lesions and that this molecular rearrangement is an early event that may precede chromosome-level alterations in prostate carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17032499      PMCID: PMC1715930          DOI: 10.1593/neo.06427

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  24 in total

Review 1.  Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes.

Authors:  J D Hooper; J A Clements; J P Quigley; T M Antalis
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

2.  Prospective BCR-ABL analysis by polymerase chain reaction (RT-PCR) in adult acute B-lineage lymphoblastic leukemia: reliability of RT-nested-PCR and comparison to cytogenetic data.

Authors:  B Gleissner; H Rieder; E Thiel; C Fonatsch; L A Janssen; B Heinze; J W Janssen; C Schoch; N Goekbuget; J Maurer; D Hoelzer; C R Bartram
Journal:  Leukemia       Date:  2001-12       Impact factor: 11.528

Review 3.  Chromosome translocations: dangerous liaisons revisited.

Authors:  J D Rowley
Journal:  Nat Rev Cancer       Date:  2001-12       Impact factor: 60.716

4.  Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer.

Authors:  Maria Johansson Soller; Margareth Isaksson; Peter Elfving; Wolfgang Soller; Rolf Lundgren; Ioannis Panagopoulos
Journal:  Genes Chromosomes Cancer       Date:  2006-07       Impact factor: 5.006

5.  Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia.

Authors:  D E Afar; I Vivanco; R S Hubert; J Kuo; E Chen; D C Saffran; A B Raitano; A Jakobovits
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

6.  The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease.

Authors:  M H Vaarala; K Porvari; A Kyllönen; O Lukkarinen; P Vihko
Journal:  Int J Cancer       Date:  2001-12-01       Impact factor: 7.396

Review 7.  Cellular and molecular pathology of prostate cancer precursors.

Authors:  C S Foster; D G Bostwick; H Bonkhoff; J E Damber; T van der Kwast; R Montironi; W A Sakr
Journal:  Scand J Urol Nephrol Suppl       Date:  2000

Review 8.  Recurrent chromosome aberrations in cancer.

Authors:  F Mitelman
Journal:  Mutat Res       Date:  2000-04       Impact factor: 2.433

9.  TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

Authors:  Scott A Tomlins; Rohit Mehra; Daniel R Rhodes; Lisa R Smith; Diane Roulston; Beth E Helgeson; Xuhong Cao; John T Wei; Mark A Rubin; Rajal B Shah; Arul M Chinnaiyan
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

Review 10.  Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer.

Authors:  Sarah Netzel-Arnett; John D Hooper; Roman Szabo; Edwin L Madison; James P Quigley; Thomas H Bugge; Toni M Antalis
Journal:  Cancer Metastasis Rev       Date:  2003 Jun-Sep       Impact factor: 9.264

View more
  101 in total

Review 1.  Roles for growth factors in cancer progression.

Authors:  Esther Witsch; Michael Sela; Yosef Yarden
Journal:  Physiology (Bethesda)       Date:  2010-04

Review 2.  TMPRSS2:ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-Analysis of Racial Differences.

Authors:  Cindy Ke Zhou; Denise Young; Edward D Yeboah; Sally B Coburn; Yao Tettey; Richard B Biritwum; Andrew A Adjei; Evelyn Tay; Shelley Niwa; Ann Truelove; Judith Welsh; James E Mensah; Robert N Hoover; Isabell A Sesterhenn; Ann W Hsing; Shiv Srivastava; Michael B Cook
Journal:  Am J Epidemiol       Date:  2017-12-15       Impact factor: 4.897

Review 3.  Stem cells in prostate cancer initiation and progression.

Authors:  Devon A Lawson; Owen N Witte
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

4.  Telomere attrition in isolated high-grade prostatic intraepithelial neoplasia and surrounding stroma is predictive of prostate cancer.

Authors:  Anthony Michael Joshua; Bisera Vukovic; Ilan Braude; Sundus Hussein; Maria Zielenska; John Srigley; Andrew Evans; Jeremy Andrew Squire
Journal:  Neoplasia       Date:  2007-01       Impact factor: 5.715

Review 5.  Oncogenic gene fusions in epithelial carcinomas.

Authors:  John R Prensner; Arul M Chinnaiyan
Journal:  Curr Opin Genet Dev       Date:  2009-02-21       Impact factor: 5.578

6.  Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.

Authors:  David J VanderWeele; Richard Finney; Kotoe Katayama; Marc Gillard; Gladell Paner; Seiya Imoto; Rui Yamaguchi; David Wheeler; Justin Lack; Maggie Cam; Andrea Pontier; Yen Thi Minh Nguyen; Kazuhiro Maejima; Aya Sasaki-Oku; Kaoru Nakano; Hiroko Tanaka; Donald Vander Griend; Michiaki Kubo; Mark J Ratain; Satoru Miyano; Hidewaki Nakagawa
Journal:  Eur Urol Focus       Date:  2018-02-15

Review 7.  The oncogene ERG: a key factor in prostate cancer.

Authors:  P Adamo; M R Ladomery
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

8.  Chinese and Western prostate cancers show alternate pathogenetic pathways in association with ERG status.

Authors:  Liyan Xue; Xueying Mao; Guoping Ren; Elzbieta Stankiewicz; Sakunthala C Kudahetti; Dongmei Lin; Luis Beltran; Daniel M Berney; Yong-Jie Lu
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

Review 9.  Recurrent gene fusions in prostate cancer.

Authors:  Chandan Kumar-Sinha; Scott A Tomlins; Arul M Chinnaiyan
Journal:  Nat Rev Cancer       Date:  2008-06-19       Impact factor: 60.716

10.  ETS gene fusions and prostate cancer.

Authors:  Wei Huang; Michelle Waknitz
Journal:  Am J Transl Res       Date:  2009-05-25       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.